Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC	Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma	Recruiting	Phase 2	2026-04-29		NCT04468061

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Dana-Farber Cancer Institute	324
Gilead Sciences	180
Merck Sharp & Dohme LLC	650

15 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Dana Farber Cancer Institute	Boston	United States	300
DF/BWCC in clinical affiliation with South Shore Hospital	South Weymouth	United States	5
DFCI @ Foxborough	Foxborough	United States	3
DFCI @ Milford Regional Hospital	Milford	United States	3
Eastern Maine Medical Center	Brewer	United States	5
Medical University of South Carolina	Charleston	United States	628
Miami Cancer Institute at Baptist Health	Plantation	United States	1
Miami Cancer Institute at Baptist Health (Kendall)	Miami	United States	1
Ohio State University Medical Center	Columbus	United States	1
Sarah Cannon Research Institute	Chattanooga	United States	1
Stamford Hospital	Stamford	United States	10
The Christ Hospital Cancer Center	Cincinnati	United States	8
The University of North Carolina at Chapel Hill	Chapel Hill	United States	19
University of Chicago Medical Center	Chicago	United States	152
University of Pennsylvania-Abramson Cancer Center	Philadelphia	United States	3